NOTE 20 - SUBSEQUENT EVENTS

As of March 29, 2024 the Company issued an aggregate of 141,425 shares of its common stock for consulting services, the Company’s Board of Directors’ stock compensation, the Company’s President stock compensation, one amended promissory note, and one promissory note valued at $126,830.

On March 08, 2024, the Company entered into a promissory note amendment #1 to the previously issued third party unsecured promissory note payable on November 10, 2023. In accordance with the amendment, the parties agreed to modify the amortization payments of the unsecured promissory note. In exchange for the modification the Company agreed to issue 15,000 shares of restricted stock to the debt holder.

On March 14, 2024, The Company issued an unsecured promissory note payable to a third party in the principal amount of $220,000. The stated interest rate is 8% per annum. The principal and interest are due on December 14, 2024. In connection with the issuance of the promissory note, the Company issued the warrant that entitles the third party to purchase 200,000 common shares. The warrant shall have a term of four years with an exercise price of $2.00. The company issued 24,000 shares of restricted stock as consideration for the loan.

On February 22, 2024, the Company’s subsidiary BioCorRx Pharmaceuticals Inc. was awarded a grant of $11,029,977 from the National Institutes of Health’s National Institute on Drug Abuse, ("NIDA"). The grant provides the Company with additional resources for the ongoing research of BICX104, a sustained release naltrexone implant for the treatment of methamphetamine use disorder. The grant provides for (i) $4,131,123 in funding during the first year, (ii) $3,638,268 during the second-year, and (iii) $3,260,586 during the third-year subject to the terms and conditions specified in the grant, including satisfactory progress of project and the availability of funds. Government grants are agreements that generally provide cost reimbursement for certain types of expenditures in return for research and development activities over a contractually defined period.

On February 01, 2024, the Company’s subsidiary BioCorRx Pharmaceuticals Inc. appointed Kate DeVarney as a member of the Board of Directors. As compensation, Ms. DeVarney will be issued common stock options to purchase shares of BioCorRx Inc’s common stock, the stock options will be issued on the last day of each fiscal quarter.

On January 5, 2024 the Company’s board of directors appointed Lou Lucido as Interim President through January 31, 2024, and transitioned to President on February 1, 2024. Mr. Lucido will remain a member of the Board of Directors, with an annual compensation of $200,000 to be paid in equity.